● Live Webinar · 25 June 2026
De-Risking Sterile Fill-Finish from Clinical to Commercial
How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success.
Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, technology transfer, quality expectations and supply continuity all need the right technical and operational support. Join Adragos Pharma for a practical webinar designed for CMC, outsourcing, MSAT, technical operations and external manufacturing teams looking to reduce risk across the sterile product lifecycle.
📅 Date: Thursday, 25 June 2026
🕒 Time: 4PM CET / 10AM EST
💻 Format: Live webinar — Free to attend
Is this your programme?
This webinar is designed for teams working on sterile products where timelines, quality and supply reliability matter. It is especially relevant for:
- CMC and pharmaceutical development teams
- Outsourcing and external manufacturing leaders
- MSAT and technical operations teams
- Sterile manufacturing and fill-finish leads
- Technology transfer and industrialisation teams
- Procurement and supply chain decision-makers
- Project and programme managers supporting clinical-to-commercial progression
The Challenge
Sterile manufacturing is where complexity becomes operational
Bringing sterile products to market requires more than capacity. Each stage introduces potential risk: process transfer, scale-up, lyophilisation, aseptic control, inspection, packaging and commercial supply planning.
Process Transfer Risk
Delays are not always caused by the science. Unclear transfer models and insufficient CDMO flexibility create execution challenges that slow programmes down.
Lyophilisation Complexity
Scale-up from clinical to commercial demands deep technical expertise, robust cycle development and rigorous qualification — up to ~70,000 vials per batch.
Aseptic Control at Scale
Aseptic manufacturing requires consistent quality governance, controlled environments, RABS technology, audit readiness and compliant fill-finish execution.
Supply Continuity
Manufacturing partners must support the full journey — from clinical development to commercial supply — with flexibility and long-term operational commitment.
Regulatory CMC Readiness
CMC submissions, stability studies, analytical validation and multi-authority compliance add significant complexity across every product stage.
Clinical-to-Commercial Continuity
Bridging clinical batches to commercial supply requires an integrated CDMO partner with depth across dosage forms — not disconnected service modules.
The right CDMO partner can help reduce these risks by combining technical depth, quality-driven execution and a network able to adapt as your product needs evolve — from first GMP batch to high-volume commercial supply.
Practical insights to help reduce programme risk
During the webinar, Adragos Pharma experts will share how an integrated sterile CDMO model can support customers across key stages of the product lifecycle. You will learn how to:
- Identify what to look for in a sterile fill-finish CDMO partner
- Reduce technical risk during lyophilisation qualification and scale-up
- Improve speed and consistency through structured technology transfer
- Integrate products into sterile manufacturing facilities with a clear execution model
- Use a flexible sterile network to support clinical-to-commercial supply
Two practical case studies
Real-world examples of how Adragos Pharma experts approach sterile programme challenges, from qualification through to commercial execution.
Lyophilisation Qualification and Scale-Up
Learn how lyophilisation performance, product temperature mapping, sublimation behaviour and process robustness can be assessed to support scale-up from clinical to commercial manufacturing.
Product Integration into a Sterile Manufacturing Facility
Explore how a structured, site-independent approach to technology transfer can support faster, more consistent product integration across a CDMO network.
A growing sterile network for clinical-to-commercial support
Adragos Pharma’s sterile manufacturing network combines aseptic fill-finish, lyophilisation, inspection, packaging and quality-driven execution across multiple sites.
Our sterile capabilities include prefilled syringes, liquid and lyophilised vials, ampoules, inspection, packaging and commercial manufacturing support. The Sterile Cluster brochure positions Adragos as a global integrated partner from clinical manufacturing to high-volume global supply.
With Maisons-Alfort and Jura as key sterile sites, Adragos Pharma is strengthening its ability to support customers with both commercial-scale execution and clinical-to-commercial flexibility.
Batch sizes from 30 to 1,500 L
Aseptic filling or terminal sterilisation process by heat
Clinical and small-scale commercial manufacturing
Sterile liquids, suspension, emulsion, viscous liquids and lyophilised
Glass vials size: 2R, 6R, 10R, 20R, 30R
Manufacturing of PFS and vials supported by CIP/SIP and active RABS technologies.
PFS: 0,5 mL and 1 mL
Vials: 6R, 10R, 7 mL, 10 mL, 15 mL, 22 mL
Meet Our Speakers
Highly skilled and well-trained scientists focused on development.
Paul Marnat
Head of Tech Transfer, Maisons-AlfortPaul Marnat is a pharmacist with more than 12 years of leadership experience in sterile pharmaceutical manufacturing, specialising in aseptic operations, GMP compliance, and technology transfer. Over the course of his career, he has held key manufacturing leadership roles across several Sanofi injectable manufacturing sites, overseeing operations and delivering complex industrial projects, including aseptic process transfers and product launches. Following the 2026 acquisition of Sanofi’s Maisons-Alfort injectable manufacturing site by Adragos Pharma, Paul has served as Head of Customer Service & Tech Transfer at Adragos Pharma. He now leads customer-facing activities and technology transfer programmes, partnering closely with internal teams to deliver efficient product transfers and dependable fill-finish operations.
Guillaume Mollandin
Head of Engineering and PMO, JuraGuillaume Mollandin is a microbiology engineer with more than 14 years of progressive leadership in pharmaceutical manufacturing and project management. He began his career advancing from Manufacturing Manager in aseptic filling and visual inspection to Head of Packaging Operations. In 2020 he joined another company as Head of Fill-Finish Operations. From 2021 to 2023 he led aseptic fill-finish process development and served as MSAT Head for a DPS growth project. Since November 2024, Guillaume has been Head of Engineering & Project Management (PMO) at Adragos Pharma’s Jura site, spearheading flexible, customer-focused fill-finish solutions.
Tobias Schlögl
Business Development DirectorTobias joined Adragos Pharma in February 2026 as Business Development Director and brings 20 years of experience in the pharmaceutical industry with profound know-how in sterile drug product manufacturing and pharmaceutical services. Working several years for Vetter Pharma, he held various positions including Quality Assurance, Project Management and, most recently, as a Business Development Manager. In addition, he was several years Head of Drug Product Manufacturing aseptic production at Boehringer Ingelheim. At Adragos Pharma, Tobias is focusing on fill & finish services. In his role he also supports the sales and marketing team and helps broaden the expertise and network for small molecules and biologic products. He contributes with his understanding of production and quality, combined with the ability to translate complex technical topics into value-added solutions for partners and stakeholders.
